CoChat

Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial

Open access
Malhotra, Atul, Bednarik, Josef, Chakladar, Sujatro, Dunn, Julia P., Weaver, Terri, Grunstein, Ron, Fietze, Ingo, Redline, Susan, Azarbarzin, Ali, Sands, Scott A., Schwab, Richard J., Bunck, Mathijs C. · 2024 · Contemporary Clinical Trials
Cited by 92

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Weight reduction is a standard recommendation for obstructive sleep apnea (OSA) treatment in people with obesity or overweight; however, weight loss can be challenging to achieve and maintain without bariatric surgery. Currently, no approved anti-obesity medication has demonstrated effectiveness in OSA management. This study is evaluating the efficacy and safety of tirzepatide for treatment of moderate to severe OSA in people with obesity. METHODS: ) and an established OSA diagnosis. SURMOUNT-OSA is made of 2 intervention-specific appendices (ISAs): ISA-1 includes participants with no current OSA treatment, and ISA-2 includes participants using positive airway pressure therapy. Overall, 469 participants have been randomized 1:1 to receive tirzepatide or placebo across the master protocol (ISA-1, n = 234; ISA-2, n = 235). All participants are also receiving lifestyle intervention for weight reduction. RESULTS: The primary endpoint for the individual ISAs is the difference in apnea hypopnea- index response, as measured by polysomnography, between tirzepatide and placebo arms at week 52. Secondary endpoints include sleep apnea-specific hypoxic burden, functional outcomes, and cardiometabolic biomarkers. The trial employs digital wearables, including home sleep testing to capture time to improvement and accelerometry for daily physical activity assessment, to evaluate exploratory outcomes. CONCLUSION: SURMOUNT-OSA brings a novel design to investigate if tirzepatide provides clinically meaningful improvement in obesity-related OSA by targeting the underlying etiology. TRIAL REGISTRATION: ClinicalTrials.gov, NCT05412004.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cct.2024.107516

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 19

  1. Grunstein, 2001, Treatment options for sleep apnoea, Drugs, 61, 237, 10.2165/00003495-200161020-00007 · DOI
  2. Grunstein, 1994, Sleep-disordered breathing and obesity, Bailliere Clin. Endocrinol. Metab., 8, 601, 10.1016/S0950-351X(05)80288-5 · DOI
  3. Smith, 1985, Weight loss in mildly to moderately obese patients with obstructive sleep apnea, Ann. Intern. Med., 103, 850, 10.7326/0003-4819-103-6-850 · DOI · Paper page
  4. Wang, 2020, Effect of weight loss on upper airway anatomy and the apnea-hypopnea index. The importance of tongue fat, Am. J. Respir. Crit. Care Med., 201, 718, 10.1164/rccm.201903-0692OC · DOI · Paper page
  5. Del Prato, 2021, Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial, Lancet, 398, 1811, 10.1016/S0140-6736(21)02188-7 · DOI · Paper page
  6. Kim, 2014, Tongue fat and its relationship to obstructive sleep apnea, Sleep, 37, 1639, 10.5665/sleep.4072 · DOI · Paper page
  7. Labarca, 2023, Sleep apnea physiological burdens and cardiovascular morbidity and mortality, Am. J. Respir. Crit. Care Med., 208, 802, 10.1164/rccm.202209-1808OC · DOI
  8. Pinilla, 2023, Hypoxic burden to guide CPAP treatment allocation in patients with obstructive sleep apnoea: a post-hoc study of the ISAACC trial, Eur. Respir. J., 10.1183/13993003.00828-2023 · DOI
  9. Sands, 2018, Quantifying the arousal threshold using polysomnography in obstructive sleep apnea, Sleep, 41, 10.1093/sleep/zsx183 · DOI · Paper page
  10. Sands, 2023, Pathophysiology underlying demographic and obesity determinants of sleep apnea severity, Ann. Am. Thorac. Soc., 20, 440, 10.1513/AnnalsATS.202203-271OC · DOI
  11. Yalamanchali, 2013, Diagnosis of obstructive sleep apnea by peripheral arterial tonometry: meta-analysis, JAMA Otolaryngol. Head Neck Surg., 139, 1343, 10.1001/jamaoto.2013.5338 · DOI · Paper page
  12. Lin, 2007, Treatment compliance in patients lost to follow-up after polysomnography, Otolaryngol. Head Neck Surg., 136, 236, 10.1016/j.otohns.2006.08.007 · DOI
  13. Patel, 2003, Continuous positive airway pressure for treating sleepiness in a diverse popultaion with obstructive sleep apnea: results of a meta-analysis, Arch Intern Med., 163, 565, 10.1001/archinte.163.5.565 · DOI · Paper page
  14. Jen, 2015, Future of sleep-disordered breathing therapy using a mechanistic approach, Can. J. Cardiol., 31, 880, 10.1016/j.cjca.2015.02.007 · DOI
  15. Sunwoo, 2022, The language of sleepiness in obstructive sleep apnea beyond the Epworth, Sleep Breath., 27, 1057, 10.1007/s11325-022-02703-1 · DOI
  16. Chen, 2021, Effect of continuous positive airway pressure on weight and local adiposity in adults with obstructive sleep apnea: a meta-analysis, Ann. Am. Thorac. Soc., 18, 1717, 10.1513/AnnalsATS.202101-060OC · DOI
  17. Drager, 2010, The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome, PLoS One, 5, 10.1371/journal.pone.0012065 · DOI · Paper page
  18. Johns, 1991, A new method for measuring daytime sleepiness: the Epworth sleepiness scale, Sleep, 14, 540, 10.1093/sleep/14.6.540 · DOI · Paper page
  19. Patel, 2018, The Epworth sleepiness scale: minimum clinically important difference in obstructive sleep apnea, Am. J. Respir. Crit. Care Med., 197, 961, 10.1164/rccm.201704-0672LE · DOI · Paper page

Cited by

See all 92

Metadata

Authors
Malhotra, A., Bednarik, J., Chakladar, S., Dunn, J. P., Weaver, T., Grunstein, R., Fietze, I., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., & Bunck, M. C.
Venue
Contemporary Clinical Trials
Publisher
Elsevier BV
Published
2024-06
Volume
141
Pages
107516
ISSN
1551-7144 (ISSN-L)
OpenAlex
W4393187269
Cited by
92
References
25
FWCI
21.76
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial. https://app.cochat.ai/papers/10.1016/j.cct.2024.107516
The paper
Malhotra, A., Bednarik, J., Chakladar, S., Dunn, J. P., Weaver, T., Grunstein, R., Fietze, I., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., & Bunck, M. C. (2024). Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2024.107516

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.